PASITHEA THERAPEUTICS CORP.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $-20.4M | $-13.9M | $-16.0M | $-13.9M | $-2.2M |
| Depreciation & Amortization | — | — | — | — | — |
| Depreciation | $32.4K | $18.9K | $18.3K | $5.1K | $1.4K |
| Amortization | — | — | — | — | — |
| Stock-Based Compensation | $297.5K | $773.7K | $592.3K | $835.1K | $471.3K |
| Net Cash from Operating Activities | $-15.2M | $-13.9M | $-12.8M | $-14.6M | $-3.2M |
| Investing Activities | |||||
| Capital Expenditures | — | — | $34.3K | $107.1K | $21.5K |
| Business Acquisitions | — | — | — | $2.2M | — |
| Net Cash from Investing Activities | $11.0K | — | — | $-2.1M | $-21.5K |
| Financing Activities | |||||
| Dividends Paid | — | — | — | — | — |
| Stock Repurchases | — | — | $3.7M | — | — |
| Net Cash from Financing Activities | $63.5M | $4.5M | — | $-3.2M | $55.9M |
| Net Change in Cash | $48.3M | $-9.4M | $-16.8M | $-19.8M | $52.7M |
| Free Cash Flow | — | — | $-12.8M | $-14.7M | $-3.2M |